| Management target | Revenue 10.0% FY27 |
|---|
| Revenue growth | Revenue up 2%; impacted by CMO supply constraints. |
|---|---|
| Margins | EBITDA margins improved 290 bps to 34-35%. |
| Demand visibility | Strong demand for vaccines and oncology; muted in general antibiotics. |
| Management confidence | High confidence in specialty pivot and double-digit growth aspirations. |
Growth
Full-year revenue grew 2%; EBITDA grew 11%. Growth was volume-led in vaccines and specialty segments despite general medicine supply headwinds.
Outlook
Aims for double-digit growth by hitting a 10% 'freshness index' from new innovative launches.
Risks
Continued supply chain dependency on external CMOs and price ceiling risks under NLEM for 40% of the portfolio.
Last quarter's promises, checked
Delivered
- Target record PAT → Delivered >1,000 Cr (= BEAT)
- Target EBITDA margin expansion → Delivered 34% vs 31.1% (= BEAT)
- Target oncology launches → Launched Zejula and Jemperli (= BEAT)
Partly delivered
- Target 10% Freshness Index → Delivered 6% (= PARTIAL)
Missed
- Target double-digit revenue growth → Delivered 2% (= MISS)
- Target CMO supply resolution → Residual impact in Q4 (= MISS)
Earnings Call Transcript filed with NSE, NSE: GLAXO. Summary written with AI assistance from the document.
GlaxoSmithKline Pharmaceuticals Ltd: key numbers
- Share price
- ₹2,755.00
- Market cap
- ₹46,671 Cr
- Revenue (annual)
- ₹3,822 Cr
- Net profit (annual)
- ₹1,036 Cr
- P/E (TTM)
- 43.7×Sector 47.4×
- Promoter holding
- 75.00%+0.00% QoQ
- FII holding
- 4.79%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from GlaxoSmithKline Pharmaceuticals Ltd
All →GlaxoSmithKline Pharmaceuticals Annual General Meeting
GSK Pharma's postal ballot approved Ms. Natland as NED and Mr. Akshikar's MD re-appointment. Both resolutions cleared with over 99% shareholder support.
GlaxoSmithKline Pharmaceuticals Annual General Meeting
GlaxoSmithKline Pharmaceuticals issued a corrigendum for its August 3, 2026, postal ballot notice, correcting a typographical error in a reported salary figure.
GlaxoSmithKline Pharmaceuticals Price Movement Clarification
GlaxoSmithKline Pharmaceuticals clarified that recent trading volume increases are purely market-driven. The company confirmed all material disclosures have been made according to SEBI regulations.
GlaxoSmithKline Pharmaceuticals Business Update
GlaxoSmithKline Pharmaceuticals received an income tax refund intimation of Rs 4.99 Crore for the assessment year 2025-2026.
- Value
- ₹4.99 Cr
GlaxoSmithKline Pharmaceuticals Annual General Meeting
GlaxoSmithKline Pharmaceuticals has issued a Postal Ballot notice for shareholder approval. The resolutions involve appointing Karine J F Natland and re-appointing Bhushan Akshikar as Managing Director.
GlaxoSmithKline Pharmaceuticals Legal & Regulatory
GlaxoSmithKline Pharmaceuticals received a ₹52.00 Crore tax refund plus ₹42.09 Crore interest income following a favorable CIT-Appeal order for assessment year 1984-85.
- Value
- ₹94.09 Cr